Improving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases
Obesity · 2025
DOI: 10.1002/oby.24287 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Obesity, 2025. Verfasst von M Jennifer Abuzzahab und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Endocrine Center, Children's Minnesota, St Paul, Minnesota, USA. Hauptthemen laut MEDLINE: Hyperphagia, Receptor, Melanocortin, Type 4. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rhythm Pharmaceuticals, Inc.
Abstract (Originalsprache)
Characteristics of hyperphagia include heightened and prolonged hunger, longer time to satiation, shorter duration of satiety, severe preoccupation with food (i.e., hyperphagic drive), abnormal food‐seeking behaviors, and distress or functional impairment when food is unavailable. Patients with melanocortin‐4 receptor (MC4R) pathway diseases including those caused by variants in one of multiple key genes of the pathway often present with hyperphagia that results in early‐onset, severe obesity because this pathway plays a critical role in regulation of hunger/satiation and energy balance. Patients with syndromic obesity (e.g., Bardet‐Biedl syndrome) may also have hyperphagia as a result of neurodevelopmental disruptions in the MC4R pathway. Genetic testing is suggested in patients with early‐onset, severe obesity and clinical features of genetic obesity (e.g., hyperphagia, neurodevelopmental differences, dysmorphic features); however, only a small percentage of individuals who meet these criteria undergo testing, potentially owing to limited availability, overlapping symptoms with other obesity types, and infrequent use of genetic testing during diagnosis. Diagnosing hyperphagia may be challenging, as no guidelines have been established for individuals with MC4R pathway diseases. Identifying these individuals is crucial to addressing the challenges of hyperphagia and associated obesity, which often limit quality of life and place overwhelming burdens on patients and families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes and Endocrine Center, Children's Minnesota, St Paul, Minnesota, USA.
- Sorbonne Université, Trousseau Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
- Sorbonne Université, Inserm, Nutrition and Obesities, Systemic Approaches Research Group, Paris, France.
- PsychoNeuroEndocrinology Research Group, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
- Imperial Centre for Endocrinology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
- Division of Pediatric Endocrinology, University of Alberta, Edmonton, Alberta, Canada.
ORCID-Profile: Steven B Heymsfield, Jesse Richards, Jack A Yanovski
Förderung
- Rhythm Pharmaceuticals, Inc
Zitieren
APA
Abuzzahab, M. J., Dubern, B., Goldstone, A. P., Haqq, A. M., Heymsfield, S. B., Miller, J. L., Richards, J., Wabitsch, M., & Yanovski, J. A. (2025). Improving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases. Obesity. https://doi.org/10.1002/oby.24287
Vancouver
Abuzzahab MJ, Dubern B, Goldstone AP, Haqq AM, Heymsfield SB, Miller JL, et al. Improving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases. Obesity. 2025. doi:10.1002/oby.24287
BibTeX
@article{Abuzzahab2025,
author = {Abuzzahab, M Jennifer and Dubern, Beatrice and Goldstone, Anthony P and Haqq, Andrea M and Heymsfield, Steven B and Miller, Jennifer L and Richards, Jesse and Wabitsch, Martin and Yanovski, Jack A},
title = {Improving the diagnosis of hyperphagia in melanocortin‐4 receptor pathway diseases},
journal = {Obesity},
year = {2025},
doi = {10.1002/oby.24287}
}
EUVIMED